Royalty Report: Drugs, Cancer, Cell Line – Collection: 294297

License Grant

The Swiss Licensor grants an exclusive option to obtain a non-exclusive, worldwide license, with the right to subl1cense through multiple levels of sublicensees, under the Licensor Patents, Technology and Know-How, any Licensee Cell Lines, and/or any Products, to propagate, have propagated, use, have used, import and have imported any Licensee Cell Lines, make, have made, manufacture, have manufactured, purify and have purified the recombinant antibody derived from the COMPANY Cell Lines, and (iii) research, develop, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import and have imported any Products, in the attached License agreement.

Upon the Licensee exercising the Commercial License Option as provided in the Services Agreement, the Swiss Licensor grants to a non-exclusive license Under the Licensor Technology to propagate, have propagated, use, have used, import and have imported Cell Lines, develop, have developed make, have made, manufacture, have manufactured,_ to make, have .made; use, have used, offer for sale, have offered for sale, distribute for sale, have distributed_ for sale, sell, have sold, import, have  Imported Products in the Licensed Field of Use, and otherwise exploit Products, lnciuding the use of products in clinical trials.

License Property

The project is to rapidly develop high-performance clonal cell line(s) for the production of Licensee Product using Licensor Genetic Elementsâ„¢ (SGEs) and SURE Cell Line(s) Development process.

Cell Line shall mean a mammalian cell line.

The patents are Matrix attachment regions and methods for use thereof, and, High Efficiency. Gene Transfer and Expressions in Mammalian Cells by a Multiple Transfection Procedure of MAR sequences.

Field of Use

Licensee is for the development of high-expression production cell lines expressing our h16C3 and 31.1 antibodies

h16C3 is a humanized mAb that we believe recognizes TSAs from pancreatic/colorectal cancers and adenocarcinoma. This monoclonal antibody may increase diagnostic and therapeutic coverage for both colon and pancreatic cancer.

License Grant

Licensor, a nonprofit cancer research institute, hereby grants to Licensee and Licensee accepts subject to the terms and conditions hereof the following licenses
(a) a non-exclusive license to use, possess, culture and employ the Licensed Cell Line at its business premises solely in the United States;
(b) a worldwide, non-exclusive license to the Licensed Monoclonal Antibody to make and have made, to use, to sell, have sold and offer for sale the Licensed Products and the Licensed Services in the field for the term of this Agreement (collectively the Licenses). Notwithstanding any other provision of this Agreement, (1) Licensee and its Affiliates shall not use the Licensed Cell Line or Licensed Monoclonal Antibody for any purpose other than that expressly described in this Agreement (2) shall not transfer the Licensed Cell Line to any third party or affiliate for any purpose except to a sublicensee as provided in this Agreement and (3) shall in no event transfer the Licensed Cell Line outside of the United States.

Licensee shall have no right or power to grant sublicenses of the Licensed Cell Line, except Licensee shall have the right to sublicense third parties to make the Licensed Monoclonal Antibody on behalf of Licensee solely for the use of Licensee, its affiliates and sublicensees subject to Licensor prior written consent.

License Property

Licensed Cell Line means the hybridoma  cell line BC3 described in Anasetti, C et. al., 'Induction of specific nonresponsiveness in unprimed human T cells by anti-CD3 antibody and alloantigen', J Exp. Med., l 72, pp. 1691-1700 (1990) and Anasetti, C. et al., Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody, Transplantation, 54, pp. 844~85 1 (1992) and all progeny, clones, derivatives and modifications thereof. Such derivatives and modifications shall not include antibodies which are not derived from or developed using the Licensed Materials and which have been entirely made with the use of information or materials available in the public domain.

Licensed Monoclonal Antibody means the monoclonal antibody BC3 and antigen binding fragments thereof, produced by or derived from the Licensed Cell Line.

Licensed Products means any product, including reagents, devices, kits and packages that contain, or are derived from, or result from the use of the Licensed Monoclonal Antibody including without limitation beads coated with the Licensed Monoclonal Antibody either by itself or in combination with other antibodies. Licensed Products does not include the Licensed Cell Line.

Licensed Services means any service performed for a third party using a Licensed Product or the Licensed Monoclonal Antibody. Services performed on biological materials from a single patient which are clinically defined to constitute a single course of treatment shall constitute the performance of a single Licensed Service procedure for purposes of this Agreement.

Field of Use

IP relates to using the monoclonal antibody that binds to the CD3 molecule for T cell stimulation for ex vivo therapeutic and research uses other than cell separation and selection.  T cells remain in a resting state until they become activated upon encountering antigens expressed by infected cells or tumor cells.

Field means any ex-vivo use for human prophylactic, therapeutic and research applications, excluding cell separation and selection applications.

License Grant

The French Licensor grants a worldwide, exclusive license under the Licensed Materials and Licensed Know-How, with the right to grant and authorize sublicenses, to make, have made, import, have imported, use, offer for sale, sell and otherwise distribute Licensed Products, practice any method, process or procedure, or otherwise exploit, in each case, Licensed Materials and Licensed Know-How for use in the Field.

License Property

Licensed Antibody shall mean the anti-CD28 antibody named B-T3 produced by the Licensed Cell Line, and any modifications.

Licensed Cell Line shall mean the B-T3 hybridoma cell line and all progeny, clones, derivatives and modifications.

Cell line B-T3 is murine IgG2a monoclonal anti-Human CD28 Antibody.

Licensed Product shall mean beads coated with the Licensed Antibody and made with use of the Licensed Materials.

Field of Use

The Field shall mean all ex vivo uses for therapeutic purposes and research applications and purposes using or relating to the Licensed Antibody or the Licensed Product.

License Grant

Hong Kong Licensor granted to the Licensee a non-exclusive, non-transferable, worldwide, royalty-bearing, sublicensable license to certain of its intellectual property, including certain patent rights associated with a proprietary cell line developed by Licensor for the exploitation of certain recombinant antibodies developed using such proprietary cell line (each, a Licensed Product).

License Property

Each Licensed Product generated under the arrangement will be produced from a transformed or transfected version of the proprietary cell line derived by Licensor (each of such transformed or transfected cell lines, a Licensed Cell Line).

The ADG20 drug substance is produced using a recombinant Chinese Hamster Ovary, or CHO, commercial cell line, fed-batch suspension cell culture and a chromatography column-based purification process.

ADG20 is designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19 as either a single or combination agent. Unlike other antibody-based therapies specifically targeting SARS-CoV-2, ADG20 has demonstrated in non-clinical studies an ability to neutralize SARS-CoV-2, including variants of concern, as well as a broad range of SARS-like viruses with neutralization potency at IC50 (half maximal inhibitory concentrations) of approximately 0.01 mcg/mL or less in live-virus cellular assays

Field of Use

Field of use is for the exploitation of certain recombinant antibodies developed using such proprietary cell line.

License Grant

Licensor hereby grants to Norway Licensee in the Field in the Territory the following royalty-bearing exclusive (even to Licensor and its Affiliates) license (including the right to grant sublicenses) under the Licensed Technology for a Product License
(a) with respect to Licensor Patents and Licensor Know-How, to Exploit Licensed Products;
(b) with respect to the Abgenix Patents, to research, develop, make, have made, use, import, offer to sell and sell Licensed Products;
(c) with respect to the Cytogen Patents, the right and license to develop, make, have made, distribute use, offer for sale, sell, have sold, import or export Licensed Products; and
(d) with respect to the Selexis Technology, to use Cell Lines for the manufacture of Licensed and/or Final Products in the Licensed Field of Use and to research, make, have made, use, offer for sale, sell, import and otherwise exploit and commercialize Final Products manufactured using the Cell Lines, including, without limitation, the use of Licensed and Final Products in Clinical Trials (with each term used in this clause (d) as defined in the Selexis Agreement).

License Property

The license is for the development and commercialization of therapeutic antibodies combining the Licensor's prostate specific membrane antigen (PSMA) antibody technology with Licensee’s targeted thorium conjugate technology.

PSMA is a protein that has been found to be amplified on the surface of >95% of prostate cancer cells and is a validated target for the detection of primary and metastatic prostate cancer. Antibody-thorium conjugates are comprised of a radioactive alpha emitter, thorium-227, linked to an antibody, in this case PSMA. The thorium conjugates bind to the surface of tumor cells and emit alpha particles that destroy tumor cells by inducing DNA double-strand breaks, with no need for uptake into the cells for efficacy.

Antibody/ies means any and all anti-human antibodies directed against the Target that are owned or Controlled by Licensor at the Effective Date or coming within its ownership or Control during the term of this Agreement, including but not limited to the fully human antibody designated as Licensor monoclonal antibody (mAb) 006.

Conjugated Antibody means any Antibody conjugated with a functional moiety intended to be used for the chelation of an alpha-emitting radionuclide.

Licensed Product means any pharmaceutical product within the Field covered by a Licensed Patent Right or generated through the use of Licensed Know How that contains or comprises a Conjugated Antibody as an active ingredient, including, in each case, all forms, presentations, formulations, dosage forms, line extensions and modes of administration thereof.
(i)
Abgenix Notwithstanding the foregoing, with respect to the Abgenix Patent Rights, 'Licensed Product' is further defined to include only products that meet the definition above and also consist of or include one or more Antibodies (as defined in the Abgenix Agreement) that bind to the Antigen (as defined in the Abgenix Agreement) and that constitute Research Program Technology (as defined in the Abgenix Agreement).
(ii)
Cytogen For purposes of the Cytogen Patents, 'covered by a Licensed Patent' means that the manufacture, use, sale, provision or practice of a Cytogen Patent would, in the absence of a license, infringe one or more claims of a Cytogen Patent.
(iii)
Selexis Notwithstanding the foregoing, with respect to the Selexis Patents and Selexis Know-How, 'Licensed Product' is further narrowed to mean a pharmaceutical preparation in final form (including, without limitation, a targeted thorium conjugate in form of a cold kit) containing any Company Protein (as defined in the Selexis Agreement) produced using a Cell Line (as defined in the Selexis Agreement) (or an active ingredient comprising a Company Protein produced using a Cell Line) for sale by prescription, over-the-counter or any other method, in any dosage form, formulation, presentation, line extension or package configuration, including without limitation such product in development where the context so requires.

Licensed Patent Rights means the Abgenix Patents, the Cytogen Patents, the Licensor Patents and the Selexis Patents, which are, to Licensors best knowledge, listed, whereby, for the avoidance of doubt shall not be exhaustive; provided, however, does not include a list of the Abgenix Patents.

Licensor Patents means any of the following
(i) any Licensed Patent Right that is designated as Licensor Patent, and
(ii) (A) any issued patent or patent application that claims priority to and/or is a divisional, continuation, reissue, renewal, reexamination, substitution or extension of any Licensor Patent listed; (B) any patents issuing on any patent application identified in (A), including any reissues, renewals, reexaminations, substitutions or extensions thereof; and (C) any foreign counterpart of any issued patent or patent application identified in (A) or (B), whether existing at the Effective Date or thereafter (all of which shall be included as Licensor Patents), and
(iii) any Patent Right Controlled by the Licensor as of the Effective Date (other than an Abgenix Patent, Cytogen Patent or Selexis Patent) or coming under Control of Licensor during the term of the Agreement to the extent, in each case, that is related to an Antibody or useful for the Development, Manufacture or Commercialization of a Licensed Product within the Field (with the exception, however, of any Patent Right that is useful solely for the Development, Manufacture or Commercialization of an Antibody in an antibody drug conjugate other than a Conjugated Antibody).

Field of Use

This license agreement with Licensee further validates the value of Licensor's PSMA antibody technology in the development of targeted cancer treatments.

Field means the following with respect to the Licensed Product
(a)
with respect to the Licensor Know-How and the Licensor Patents, all human therapeutic (including prophylactic) indications;
(b)
with respect to the Abgenix Patents, human therapeutic, preventative (prophylactic) medical use;
(c)
with respect to the Cytogen Patents, any and all means of developing, making, having made, distributing, using, offering for sale, selling, having sold, importing or exporting any Field Antibody (as defined in the Cytogen Agreement); and
(d)
with respect to the Selexis Know-How and Selexis Patent Rights, human therapeutic, preventative (prophylactic) medical use.

License Grant

Licensor grants to the Licensee of the United Kingdom, and its Affiliates, an exclusive license under Licensor Background Patent Rights, Licensor Future Patent Rights, Licensor Alliance IP Rights, Licensor’s interest in Joint Alliance IP Rights, and Licensor Know-How to develop, have developed, make, have made, use, sell, have sold, and import Cellular Assay Products throughout the Territory in the Cellular Assay Products Field.

Licensor grants
—  a non-exclusive, irrevocable license under Licensor’s Alliance IP Rights, Licensor’s interest in Joint Alliance IP Rights and Licensor Know-How to develop, make, use, sell, have sold, and import products throughout the relevant territories in the Limited Field and,
—  a non-exclusive, irrevocable license under Licensor’s Alliance IP Rights and Licensor’s interest in Joint Alliance IP Rights to develop, have developed, make, have made, use, sell, have sold, and import products throughout the relevant territories in the Limited Field.

Licensor grants an option to negotiate in good faith and on commercially reasonable terms
—  an exclusive, payable license, with the right to sublicense for the Limited Field under Licensor Alliance IP Rights, and Licensor’s interest in Joint Alliance IP Rights, and;
—  a sub-license for the Cellular Assay Products Field in the Territory.

License Property

The patents and know-how are for certain intellectual property rights related to the propagation and differentiation of human embryonic derived cells.

Field of Use

The Cellular Assay Products Field shall mean the use of Cellular Assay Products for in vitro assay applications, including but not limited to drug discovery and development, drug monitoring, drug toxicology testing, and consumer products testing, but excluding the use of any Cellular Assay Product in any therapeutic or diagnostic application.

The Licensor Field shall mean therapies that comprise, or are derived from, or developed or manufactured using, human embryonic stem cells.

The Limited Field shall mean products or services that contain cells that comprise, or are derived from, or manufactured using, human embryonic stem cells (and not human induced pluripotent stem cells) in markets outside of the Licensor Field and the Cellular Assay Products Field.

Cellular assay products derived from human embryonic stem cells (hESCs) is for use in drug discovery, development and toxicity screening.